Target intelligence / Profile preview

Synovial sarcoma X breakpoint 2 (SSX2)

Target
SSX2
Molecular classification
Transcription factor, Other
01

Overview

Synovial sarcoma X breakpoint 2 (SSX2), also known as cancer/testis antigen 5.2 (CT5.2) or HOM-MEL-40, is a member of the highly homologous SSX family of nuclear proteins. Under normal physiological conditions, SSX2 expression is highly restricted to the testis (specifically spermatogonia) and is minimally expressed in the thyroid, making it an immune-privileged cancer-testis antigen. However, SSX2 is aberrantly reactivated and overexpressed in a wide variety of malignancies, including synovial sarcoma, melanoma, prostate cancer, pancreatic cancer, breast cancer, and acute myeloid leukemia. In synovial sarcoma, a characteristic t(X;18)(p11.2;q11.2) chromosomal translocation fuses the SS18 gene to SSX2 (or SSX1/SSX4), creating an oncogenic SS18-SSX fusion protein that acts as a transcriptional regulator and drives tumorigenesis.

Due to its highly restricted expression in normal tissues and high immunogenicity in cancer patients, SSX2 is an attractive target for cancer immunotherapy. Therapeutic strategies targeting SSX2 include DNA vaccines (such as pTVG-SSX2), adoptive T-cell therapies (such as the multi-tumor-associated antigen T-cell therapy MT-601), and engineered TCR-T or CAR-T cell therapies. Additionally, epigenetic modifying agents like DNA methyltransferase inhibitors (e.g., decitabine) and histone deacetylase inhibitors (e.g., trichostatin A) are utilized to upregulate SSX2 expression in tumor cells, thereby enhancing their susceptibility to SSX2-targeted immunotherapies.

Other names
Protein SSX2Cancer/testis antigen 5.2CT5.2Tumor antigen HOM-MEL-40HOM-MEL-40Synovial sarcoma, X breakpoint 2Cancer/testis antigen family 5, member 2aCT5.2ASSX2B
02

Mechanism of action

Adoptive cellular immunotherapy, active immunotherapy, DNA vaccination, DNA methyltransferase inhibition, and histone deacetylase inhibition.

03

Biological functions

Transcription regulationImmune responseCell proliferationOther
04

Disease associations

Cancer
05

Safety considerations

Off-target toxicity due to low-level expression in normal tissues like the thyroidImmune evasion via upregulation of PD-L1 on tumor cells and PD-1 on T cellsCytokine release syndrome associated with CAR-T or TCR-T therapiesOn-target, off-tumor toxicityAntigen loss or downregulation leading to tumor escape
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

SSX2 expressionHLA-A*02:01 genotypeSSX2-specific T-cell responseSSX2-specific IgG antibodiesCirculating tumor cells expressing SSX2

Beyond the preview

Go deeper on Synovial sarcoma X breakpoint 2 (SSX2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synovial sarcoma X breakpoint 2 (SSX2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call